Company Profile
Scancell’s mission is to deliver potent and safe active immunotherapies for a cancer-free future. Our Immunobody® and Moditope® active immunotherapies are off-the-shelf treatments designed to deliver favourable safety, low toxicity and durable systemic immune responses. Our lead product inzitagene plasmivec, an Immunobody® DNA active immunotherapy, activates a strong and safe lasting immune response in patients with advanced melanoma, with the potential to set a new benchmark in the standard of care. The lead Moditope® peptide active immunotherapy has also shown encouraging Phase 2 data in a broad range of solid tumors.
Scancell’s wholly owned subdisiary, Glymab Therapeutics Ltd., has two antibody technologies, GlyMab® (anti-glycans) and AvidiMab®, with the potential to treat many solid cancers. GlyMab® antibodies targets glycans or sugars that are added onto proteins and / or lipids are supported by comprehensive preclinical data, resulting in two partnering deals with Genmab.
Scancell is incorporated in the UK where its main operations are located.
About Scancell
Scancell (LSE:SCLP;) is a late-stage clinical biotechnology company. The lead product, inzitagene plasmivec, is an off-the-shelf DNA ImmunoBody® administered needle-free that has demonstrated a favorable safety profile and clinically meaningful activity both as a monotherapy, in a Phase 1 trial, and in combination with checkpoint therapies in a Phase 2 trial in patients with melanoma. Modi-1, is a ModiTope peptide currently being evaluated in a Phase 2 study in head & neck and renal cancers. In addition, Scancell’s wholly owned subsidiary, GlyMab Therapeutics Ltd., is advancing a pipeline of high affinity GlyMab® antibodies targeting tumor specific glycans, two of which have been licensed for further development to Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.
